Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIOL study of first-line osimertinib in EGFR-mutated non-small cell lung cancer
2024-513881-20-00Phase 2Completed
- Sponsor
- Vestre Viken Hospital Trust
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Vestre Viken Hospital Trust. Primary endpoint: Objective response rate. Started Nov 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513881-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513881-20-00.